Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2022-06-27

Clinical Trial Update: Safety and Efficacy Study of RA101495 in Subjects With Generalized Myasthenia Gravis [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating RA101495 in generalized myasthenia gravis completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • RA101495 (RA101495)

Snippet

Sponsor: Ra Pharmaceuticals | Conditions: Generalized Myasthenia Gravis | Phase 2 | Status: COMPLETED | Results posted: 2022-06-27